# Rivaroxaban - Percutaneous Coronary Intervention

> **NCT05541757** · — · COMPLETED · sponsor: **Bursa Postgraduate Hospital** · enrollment: 30 (actual)

## Conditions studied

- Coronary Artery Disease
- Atrial Fibrillation

## Interventions

- **DRUG:** In vitro heparin

## Key facts

- **NCT ID:** NCT05541757
- **Lead sponsor:** Bursa Postgraduate Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-03-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05541757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05541757, "Rivaroxaban - Percutaneous Coronary Intervention". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05541757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*